MedTrace Logo

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

NCT01076205 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7229

Last updated 2019-02-07

Study results available
· View outcomes & findings →

Summary

The AGIL study was designed to evaluate the effectiveness and safety of adalimumab over 5 years in routine daily clinical practice in Germany, with a focus on the impact of therapy on employment-related outcomes.

Conditions

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Henning Kleine, PhD · AbbVie Deutschland GmbH & Co. KG, Medical Department

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-12
Primary Completion
2017-09-14
Completion
2017-09-14

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01076205 on ClinicalTrials.gov